Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders' Collaborative Consortium (EORTC 1419).

Détails

Ressource 1Télécharger: 37277265.pdf (1611.09 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_58117B8EE829
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders' Collaborative Consortium (EORTC 1419).
Périodique
European journal of cancer
Auteur⸱e⸱s
Hertler C., Felsberg J., Gramatzki D., Le Rhun E., Clarke J., Soffietti R., Wick W., Chinot O., Ducray F., Roth P., McDonald K., Hau P., Hottinger A.F., Reijneveld J., Schnell O., Marosi C., Glantz M., Darlix A., Lombardi G., Krex D., Glas M., Reardon D.A., van den Bent M., Lefranc F., Herrlinger U., Razis E., Carpentier A.F., Phillips S., Rudà R., Wick A., Tabouret E., Meyronet D., Maurage C.A., Rushing E., Rapkins R., Bumes E., Hegi M., Weyerbrock A., Aregawi D., Gonzalez-Gomez C., Pellerino A., Klein M., Preusser M., Bendszus M., Golfinopoulos V., von Deimling A., Gorlia T., Wen P.Y., Reifenberger G., Weller M.
ISSN
1879-0852 (Electronic)
ISSN-L
0959-8049
Statut éditorial
Publié
Date de publication
08/2023
Peer-reviewed
Oui
Volume
189
Pages
112913
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Median survival with glioblastoma remains in the range of 12 months on population levels. Only few patients survive for more than 5 years. Patient and disease features associated with long-term survival remain poorly defined.
European Organization for Research and Treatment of Cancer (EORTC) 1419 (ETERNITY) is a registry study supported by the Brain Tumor Funders Collaborative in the US and the EORTC Brain Tumor Group. Patients with glioblastoma surviving at least 5 years from diagnosis were identified at 24 sites in Europe, US, and Australia. In patients with isocitrate dehydrogenase (IDH) wildtype tumours, prognostic factors were analysed using the Kaplan-Meier method and the Cox proportional hazards model. A population-based reference cohort was obtained from the Cantonal cancer registry Zurich.
At the database lock of July 2020, 280 patients with histologically centrally confirmed glioblastoma (189 IDH wildtype, 80 IDH mutant, 11 incompletely characterised) had been registered. In the IDH wildtype population, median age was 56 years (range 24-78 years), 96 patients (50.8%) were female, 139 patients (74.3%) had tumours with O <sup>6</sup> -methylguanine DNA methyltransferase (MGMT) promoter methylation. Median overall survival was 9.9 years (95% confidence interval [95% CI] 7.9-11.9). Patients without recurrence experienced longer median survival (not reached) than patients with one or more recurrences (8.92 years) (p < 0.001) and had a high rate (48.8%) of MGMT promoter-unmethylated tumours.
Freedom from progression is a powerful predictor of overall survival in long-term survivors with glioblastoma. Patients without relapse often have MGMT promoter-unmethylated glioblastoma and may represent a distinct subtype of glioblastoma.
Mots-clé
Humans, Female, Young Adult, Adult, Middle Aged, Aged, Male, Glioblastoma/genetics, Glioblastoma/therapy, Glioblastoma/pathology, Isocitrate Dehydrogenase/genetics, DNA Methylation, Neoplasm Recurrence, Local/genetics, Prognosis, Brain Neoplasms/genetics, Brain Neoplasms/therapy, Brain Neoplasms/diagnosis, DNA Modification Methylases/genetics, DNA Repair Enzymes/genetics, Retrospective Studies, IDH, MGMT, Outcome, Registry, Wildtype
Pubmed
Web of science
Open Access
Oui
Création de la notice
08/06/2023 13:58
Dernière modification de la notice
20/12/2024 7:07
Données d'usage